Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients

Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients : ProCOVRA

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04679272

Acronym

ProCOVRA

Enrollment

2000

Registered

2020-12-22

Start date

2020-12-01

Completion date

2021-02-01

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Rheumatoid Arthritis

Keywords

DMARDs, Biotherapy

Brief summary

COVID-19 is an infectious disease caused by SARS-CoV2 virus. The objective of our study is to analyze the progression and the severity of COVID-19 in patients with RA. Indeed, few data are available on this subject, and this would allow us to improve management of COVID-19 in these potential at-risk patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- Confirmed COVID-19 diagnosis (positive PCR or serology) in RA patients or healthy controls.

Exclusion criteria

* Age under 18 years old * Suspected COVID-19 diagnosis (typical symptoms without a positive PCR or serology)

Design outcomes

Primary

Measure	Time frame	Description
Hospitalization rates for COVID-19	1 day	Proportion of hospitalized patients in RA group or control group. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Secondary

Measure	Time frame	Description
Pulmonary comorbidities, corticosteroids or DMARDs use	1 day	Type and severity of patients pulmonary comorbidities and treatment by corticosteroids or DMARDs in RA group From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Age	1 day	Patients demographics From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Critical care transfer rate for COVID-19 and death due to COVID-19	1 day	Proportion of patients transferred in critical care for COVID-19 or deaths due to COVID-19 From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Type of clinical presentation	1 day	Patients COVID-19 clinical presentation From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Type of associated treatments	1 day	From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.
Number of Participants with co-morbidities	1 day	Patients comorbidities From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery.

Countries

France

Outcome results